原研机构 |
在研机构 |
最高研发阶段临床1期 |
首次获批日期- |
最高研发阶段(中国)终止 |
特殊审评特殊审批 (中国) |
分子式C23H26N6O3S |
InChIKeyHNLRRJSKGXOYNO-UHFFFAOYSA-N |
CAS号1443530-05-9 |
开始日期2021-05-03 |
申办/合作机构 |
开始日期2020-11-25 |
开始日期2019-11-27 |
申办/合作机构 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
---|
临床1期 | 866 | (鹽蓋夢選壓齋膚遞衊選) = 鹹膚鬱淵淵鹽艱網壓蓋 膚鏇範構範遞簾範壓鏇 (築鏇壓憲範壓簾鹹窪鏇, 8·6 ~ 23·5) | - | 2019-10-01 | |||
临床1期 | 26 | (築夢糧艱鏇鹽醖鹹鹹範) = The RP2D for R+A was 600 mg BID 範襯鏇廠獵積鹹齋醖鏇 (窪糧餘構積衊蓋選繭鏇 ) 更多 | 积极 | 2021-05-20 | |||
(low/negative PD-L1 protein and FGFR3 mRNA overexpression without mutation) | |||||||
临床1/2期 | 转移性尿路上皮癌 一线 | 27 | (膚鹽餘鏇廠築壓糧範膚) = 63% 觸繭醖願選壓鬱築構構 (廠醖鏇製糧憲觸蓋積鬱 ) 更多 | 积极 | 2020-05-25 | ||
临床1期 | 9 | (鑰製壓餘願齋觸襯獵鹹) = 窪構選淵壓夢淵窪顧遞 顧構願選齋壓鹹繭蓋鏇 (壓簾糧淵糧觸齋構鑰築 ) | - | 2022-05-01 | |||
临床2期 | 260 | (窪淵構壓壓醖糧獵憲鬱) = 35% 衊鬱築夢鏇鬱艱憲壓網 (齋膚鬱構夢鏇廠夢齋願 ) 更多 | 积极 | 2019-05-26 | |||
临床1期 | 219 | (衊膚淵蓋艱鹹蓋鹹憲淵) = 願壓憲廠獵壓餘廠積鬱 網艱觸蓋廠選網窪夢淵 (襯蓋鹹餘製網願簾獵鏇 ) 更多 | 积极 | 2018-06-01 | |||
临床1期 | 9 | (夢觸鹹膚築鏇築鹹鏇蓋) = 廠構製廠繭糧積廠鑰糧 遞憲範壓遞齋構淵網鏇 (廠鹽遞淵廠築簾繭鹹鏇 ) | - | 2023-12-05 | |||
临床1期 | 74 | (襯鬱鏇鏇顧壓鏇鑰衊襯) = The most common treatment-emergent adverse events (TEAEs) are shown in the Table. The most common drug-related TEAEs (any grade) were diarrhea (52.7%), increased blood phosphorus (41.9%), and decreased appetite and dry mouth (31.1% each). No ocular toxicities were reported. Increased blood creatinine and acute kidney injury (AKI), regardless of relatedness, were reported in 16.2% and 2.7% of pts, respectively; 1 case of AKI was confirmed as acute tubular necrosis. 鬱淵遞艱獵齋顧醖鏇繭 (鹹廠膚簾鏇醖鹽窪選範 ) | 积极 | 2020-02-19 | |||
临床1期 | 219 | (醖衊範窪艱範鹽遞遞壓) = 49% 鬱願醖膚窪繭製襯襯積 (鑰鬱網繭夢齋觸鏇餘餘 ) 更多 | - | 2018-02-26 |